Case report finds chidamide maintenance may delay progression in advanced mycosis fungoides, indicating need for further research.
Primary cutaneous T-cell lymphoma (CTCL) comprises a group of rare, aggressive non-Hodgkin lymphomas, of which mycosis fungoides (MF) and Sézary syndrome are the most common subtypes. In the absence of a universally accepted standard of care for advanced stages, allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers curative potential; however, post-transplant relapses remains the principle cause of treatment failure, making effective maintenance strategies crucial. This report describes the case of a young woman with stage IVA MF who, following failure of multiple conventional therapies, underwent haploidentical allo-HSCT and initiated chidamide maintenance upon achieving complete remission. This approach successfully consolidated remission for 10 months; however, the patient relapsed at 11 months post-transplant and ultimately died of neutropenic septic shock. This case suggests that post-transplant chidamide maintenance may have value in delaying disease progression in advanced MF; however, treatment-related toxicities and the risk of relapse remain significant clinical challenges requiring further investigation.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: